Skip to Content

Clorox Co

View Stock Summary
Morningstar Rating for Stocks Fair Value Economic Moat Capital Allocation

Clorox Earnings: Muted Sales and Profits, but on Track to Close the Book on 2023 Cyberattack

The market soured on Clorox after it printed tempered third-quarter marks, sending shares down at a low- to mid-single-digit percentage clip in after-hours trading. However, we never expected Clorox’s turnaround would head due north. Thus, we don’t anticipate any change to our $169 fair value estimate, beyond a low-single-digit bump for the time value of money. With shares at around a 15% discount to our intrinsic valuation, we think investors would be wise to stock up on this wide-moat company.

Free Trial of Morningstar Investor

Get our analysts’ objective, in-depth, and continuous investment coverage of CLX so you can make buy / sell decisions free of market noise.

Start Free Trial

Sponsor Center